NEPTUNUS (H-52378)
Description
Content
A randomized, double-blind, placebo-controlled, 2-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (NEPTUNUS-1).
Contact
Phone 1: 713–798–4205
IRB: H-52378
Status:
Active
Created:
